Gardasil News and Research

RSS

Gardasil is a vaccine that prevents the types of genital human papillomavirus (HPV) that cause most cases of cervical cancer and genital warts. The vaccine, Gardasil, is given in three shots over six-months. The vaccine is routinely recommended for 11 and 12 year old girls. It is also recommended for girls and women age 13 through 26 who have not yet been vaccinated or completed the vaccine series.

GAVI Alliance to fund HPV immunization projects in 8 countries

The GAVI Alliance "is to help protect more than 180,000 girls in eight countries across Africa and Asia from cervical cancer by funding immunization projects with vaccines from Merck and GlaxoSmithKline," Reuters reports in an article examining the group's efforts to vaccinate young women with Merck's Gardasil and GSK's Cervarix, "the world's only two approved shots designed to protect against the sexually transmitted human papillomavirus (HPV) that causes the vast majority of cervical cancer cases."

5 Feb 2013

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012.

1 Feb 2013

Scientists figure out how to dodge HPV-triggered cancers by vaccination

In 2009, more than 30,000 people in the U.S. learned they had cancer linked to the human papillomavirus, or HPV. This virus is best known for causing cervical cancer, but it's also the culprit behind many cancers of the mouth, throat, anus, and genitals. Unlike many forms of cancer, for which we lack the knowledge and tools to prevent, scientists have figured out how to dodge HPV-triggered cancers — by HPV vaccination.

19 Jan 2013

Virginia Women's Center to participate in new HPV and cervical cancer vaccine clinical trial

Virginia Women's Center has been selected to participate in a nationwide clinical trial, one that will ultimately hope to prevent the human papillomavirus virus (HPV) from progressing into cervical cancer and treat women who have HPV and the precancerous lesions associated with it. The Richmond-area OB-GYN practice has participated in over 50 clinical research studies since 1997, all of which have contributed to the future of safe and effective medicine for women.

4 Dec 2012

Taking technology from the lab to the patient: SMART Arm™: Hand of hope for stroke survivors

Creating a viable commercial product from its beginnings as a research concept through to a final product patients can use is a long, difficult and often expensive process. However, as David Henderson, the Managing Director of UniQuest, one of the leading technology transfer companies in the Asia Pacific region explains, a focus on patient needs is vital for developing a successful product.

15 Oct 2012

Gardasil does not increase sexual activity in girls

The human papillomavirus (HPV) vaccine known as Gardasil is not associated with an increase in pregnancy, sexually transmitted infections, or contraceptive counseling, according to a Kaiser Permanente study published online today in the journal Pediatrics.

15 Oct 2012

Bivalent HPV vaccine has cross-protective effect, but could wane over time

The bivalent vaccine for human papillomavirus types 16 and 18 appears to be more efficacious against outcomes associated with nonvaccine types 31, 33, and 45 than its quadrivalent counterpart, show results of a systematic review and meta-analysis.

5 Oct 2012

Paper provides overview on preventing invasive cervical cancer

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida and The Ohio State University have published a paper in the September issue of Cancer Epidemiology, Biomarkers & Prevention that provides an overview on preventing invasive cervical cancer.

28 Sep 2012

Uganda launches vaccination campaign against cervical cancer

"The government of Uganda has launched a vaccination campaign against cervical cancer -- the most common type of cancer among Ugandan women -- but there are already fears a nationwide rollout might be jeopardized by lack of funds," IRIN reports.

7 Sep 2012

Pathologist identifies HPV DNA fragments in post-mortem samples after Gardasil vaccination

According to Norma Erickson, President of SaneVax Inc., testimony provided for a coroner's inquest into the death of Jasmine Renata in New Zealand by Dr. Sin Hang Lee, a pathologist on the medical staff at Connecticut's Milford Hospital, revealed the discovery of HPV DNA fragments in post-mortem samples 6 months after Gardasil vaccination.

9 Aug 2012

Roundup: Ore. Gov. suggests malpractice reform; Mass. Gov. proposes new scrutiny for health care providers; Texas has offered HPV vaccine since 2007

The state can cut health care costs and reduce the number of medical-related lawsuits by requiring earlier notification of injuries as well as pretrial mediation, according to a recommendation Gov. John Kitzhaber issued Wednesday. The product of closed-door talks between representatives of interest groups including the Oregon Medical Association and the Oregon Trial Lawyers Association, Kitzhaber's recommendation now goes to a work group including lawmakers, a trial lawyer and doctor that begins public meetings next week.

27 Jul 2012

Allied Healthcare increases stake in Coridon to over 44%

Allied Healthcare Group (ASX: AHZ) announced today that post the recent capital raising it has invested a further $1 million into Coridon, increasing its holding in the company to 44.4%. Allied has increased its investment in Coridon as the Company progresses towards its Phase I study for a herpes vaccine and makes further progress on its HPV therapeutic vaccine program.

26 Apr 2012

Canadian docs recommend HPV vaccine for boys

Girls have had access to free HPV vaccinations for five years - administered to protect them against cervical cancer - and this week, the Canadian Cancer Advocacy Coalition called on provincial governments to pay for the vaccine for boys as well. In January, the National Advisory Committee on Immunization recommended HPV vaccination for males aged nine to 25.

16 Apr 2012

Young girls face increased risk of side effects after Gardasil vaccination

Younger girls are more likely than adult women to report side effects after receiving Gardasil, the human papillomavirus vaccine.

4 Apr 2012

HPV vaccine recommended for boys

The American Academy of Pediatrics has recommended boys -; not just girls -; be vaccinated against HPV, though questions about its cost-effectiveness remain.

29 Feb 2012

HPV vaccine now recommended for boys: American Academy of Pediatrics

Pediatricians in the U.S. say it's now time for boys, as well as girls, to be vaccinated against human papillomavirus or HPV. The American Academy of Pediatrics has updated its guidance to parents and doctors in favor of routine immunization for boys against the virus. Earlier the AAP had said it was OK to vaccinate boys against the HPV, but it only became part of the pediatricians' official schedule of recommended vaccines this month.

28 Feb 2012

HPV transmission via oral sex practices suggests research

A new study suggested that an estimated 7% of American teens and adults carry the human papillomavirus in their mouths. This may help health experts finally understand why rates of mouth and throat cancer have been climbing for nearly 25 years. The evidence additionally makes it clear that oral sex practices play a key role in transmission.

29 Jan 2012

Gardasil – cervical cancer vaccine offered to all boys as well

Soon all adolescent boys may be vaccinated against the sexually transmitted disease that causes some forms of cancer under an extension of a scheme now available to girls, the Australian government's expert panel has recommended. The committee adds that the shots would also widen immunity to the virus, which would further reduce the risk to women and stem the spread of genital warts in both sexes.

19 Dec 2011

HPV test outshines Pap smears for detection of early cervical cancers

A new trial involving nearly 40,000 women in the Netherlands showed that testing for the human papillomavirus, or HPV allowed doctors to detect abnormal cervical cells earlier and prevent more cases of cervical cancer than administering pap smears alone.

18 Dec 2011

Mass immunization with cervical cancer vaccine switched to a more effective variety

Cervarix is currently offered to girls aged 12 and 13 years to protect against strains of the sexually transmitted human papillomavirus (HPV), which causes most cases of cancer of the cervix, the neck of the womb. Cervarix was picked by the Labour government for the first four-year phase of the NHS programme in 2008 because it offered ‘best overall value’ and more than five million doses have been given.

27 Nov 2011